Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer’s disease

Mega, 1999, The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease, Arch. Neurol., 56, 1388, 10.1001/archneur.56.11.1388 Giacobini, 2000, Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer’s disease, Alzheimer Dis. Assoc. Disord., 14 suppl 1, S3, 10.1097/00002093-200000001-00002 Alhainen, 1993, The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer’s disease, J. Neural. Transm. Park. Dis. Dement. Sect., 5, 185, 10.1007/BF02257673 Schneider, 1991, Do blood pressure and age predict response to tacrine (THA) in Alzheimer’s disease? A preliminary report, Psychopharmacol. Bull., 27, 309 Farlow, 1998, Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease, Neurology, 50, 669, 10.1212/WNL.50.3.669 Alhainen, 1993, Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy, Acta Neurol. Scand., 149, 16 Kaufer, 1996, Effect of tacrine on behavioral symptoms in Alzheimer’s disease: An open-label study, J. Geriatr. Psychiat. Neurol., 9, 1, 10.1177/089198879600900101 Farlow, 2001, Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression, Arch. Neurol., 58, 417, 10.1001/archneur.58.3.417 Mega, 2000, Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer’s disease, J. Neuropsych. Clin. Neurosci., 12, 209, 10.1176/appi.neuropsych.12.2.209 Tanaka, 2003, Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer’s disease patients, Dement. Geriatr. Cogn. Disord., 16, 119, 10.1159/000070998 Blasko, 2004, Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions, Pharmacology, 72, 1, 10.1159/000078625 Dik, 2003, Insulin-like growth factor I (IGF-I) and cognitive decline in older persons, Neurobiol. Aging, 24, 573, 10.1016/S0197-4580(02)00136-7 Garcia, 2006, Association of insulin-like growth factor-1 receptor polymorphism in dementia, Dement. Geriatr. Cogn. Disord., 22, 439, 10.1159/000095803 Carro, 2004, The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer’s disease, Eur. J. Pharmacol., 490, 127, 10.1016/j.ejphar.2004.02.050 Gasparini, 2003, Potential roles of insulin and IGF-I in Alzheimer’s disease, Trend Neurosci., 26, 404, 10.1016/S0166-2236(03)00163-2 Watanabe, 2005, Relationship between serum insulin-like growth factor-1 levels and Alzheimer’s disease and vascular dementia, J. Am. Geriatr. Soc., 53, 1748, 10.1111/j.1532-5415.2005.53524.x Matsui, 1999, Absorption, distribution, metabolism, and excretion of donepezil (aricept) after a single oral administration to rat, Drug Metab. Dispos., 27, 1406 Rivera, 2005, Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine, J. Alzheimer Dis., 8, 247, 10.3233/JAD-2005-8304 McKhann, 1984, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 Folstein, 1975, Mini-mental state: a practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res., 12, 189, 10.1016/0022-3956(75)90026-6 Hughes, 1982, A new clinical scale for the staging of dementia, Br. J. Psychiatr., 140, 566, 10.1192/bjp.140.6.566 Reisberg, 1988, Functional assessment staging (FAST), Psychopharmacol. Bull., 24, 653 Honma, 1991, Development of a new rating scale for dementia in the elderly: mental function impairment scale (MENFIS), Jap. J. Geriatr. Psychiatr., 2, 1217 G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, J.L. Cummings J.C. Masdeu, P. Scheinberg, Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop, Neurology, 43, 1993, pp. 250–260. Sands, 1999, Assessment individual patients for cognitive benefits from acetylcholinesterase inhibitors, Alzheimer Dis. Assoc. Disord., 13, 26, 10.1097/00002093-199903000-00004 Yamamoto, 2005, High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia, J. Am. Geriatric. Soc., 53, 583, 10.1111/j.1532-5415.2005.53204.x Watanabe, 2003, Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis, Am. J. Hypertens., 16, 754, 10.1016/S0895-7061(03)00985-3 Arwert, 2005, The relation between insulin-like growth factor I levels and cognition in healthy elderly: a meta-analysis, Growth Horm. IGF Res., 15, 416, 10.1016/j.ghir.2005.09.001 Paolisso, 1997, Serum levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in healthy centanarians: relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function, J. Clin. Endocrinol. Metab., 82, 2204, 10.1210/jc.82.7.2204 Okereke, 2007, Plasma IGF-1 levels and cognitive performance in older women, Neurobiol. Aging, 28, 135, 10.1016/j.neurobiolaging.2005.10.012 Landi, 2007, Free insulin-like growth factor-I and cognitive function in older persons living in community, Growth Horm. IGF Res., 17, 58, 10.1016/j.ghir.2006.11.001 Schulingkamp, 2000, Insulin receptors and insulin action in the brain review and clinical implications, Neurosci. Biobehav. Rev., 24, 855, 10.1016/S0149-7634(00)00040-3 Castro-Alamancos, 1994, Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide, Proc. Natl. Acad. Sci. USA, 91, 10203, 10.1073/pnas.91.21.10203 Gluckman, 1992, A role for IGF-1 in the rescure of CNS neurons following hypoxic/ischemic injury, Biochem. Biophys. Res. Commun., 182, 593, 10.1016/0006-291X(92)91774-K Wu, 1996, Activation of the I-LGF-1 receptor inhibits tumor necrosis factor-induced cell death, J. Cell Physiol., 168, 499, 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K Carro, 2002, Serum insulin-like growth factor-I regulates brain amyroid-β levels, Nat. Med., 8, 1390, 10.1038/nm1202-793 Carro, 2006, Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer’s-like neuropathology in rodents: new cues into the human disease?, Neurobiol. Aging, 27, 1618, 10.1016/j.neurobiolaging.2005.09.039 Steen, 2005, Impaired insulin and insulin-like growth factor expression and signalling mechanisms in Alzheimer’s disease-is this type 3 diabetes?, J. Alzheimer Dis., 7, 63, 10.3233/JAD-2005-7107 Mustafa, 1999, Decreased plasma insulin-like growth factor-I level in familial Alzheimer’s disease patients carrying the Swedish APP 670/671 mutation, Dement. Geriatr. Cogn. Disord., 10, 446, 10.1159/000017188 Alvarez, 2007, Serum TNF-alpha levels are increased and correlated negatively with free IGF-I in Alzheimer disease, Neurobiol. Aging, 28, 533, 10.1016/j.neurobiolaging.2006.02.012 Lombardi, 1999, Characterization of cytokine production screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease individuals, J. Neuroimmunol., 97, 163, 10.1016/S0165-5728(99)00046-6 Kinoshita, 2007, The relationship in Japanese infants between a genetic polymorphism in the promoter region of the insulin-like growth factor I gene and the plasma level, Neonatology, 92, 116, 10.1159/000101062 Harada, 2007, Effect of topical application of capsaicin and its related compounds on dermal insulin-like growth factor-I levels in mice and on facial skin elasticity in humans, Growth Horm. IGF Res., 17, 171, 10.1016/j.ghir.2006.12.005 Obermayr, 2005, The age-related down-regulation of the growth hormone/insulin-like growth factors-I axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer’s disease, Exp. Gerontol., 40, 157, 10.1016/j.exger.2004.11.001 Jones, 1995, Insulin-like growth factors and their binding proteins: biological actions, Endocr. Rev., 16, 3 Vignery, 1996, The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts, Bone, 18, 331, 10.1016/8756-3282(96)00017-8 Harada, 2005, Contribution of capsaicin-sensitive sensory neurons to antithrombin-induced reduction of ischemia/reperfusion-induced liver injury in rats, Thromb. Haemost., 93, 48, 10.1160/TH04-02-0106 Harada, 2007, Stimulation of sensory neurons by capsaicin increases tissue levels of IGF-I thereby reducing reperfusion-induced apoptosis in mice, Neuropharmacology, 52, 1303, 10.1016/j.neuropharm.2007.01.016 Tanaka, 2004, Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer’s disease, J. Neurol. Sci., 225, 135, 10.1016/j.jns.2004.07.009 Winblad, 2006, Severe Alzheimer’s disease study group, donepezil in patients with severe Alzheimer’s disease: double bond, parallel-group, placebo-controlled study, Lancet, 367, 1057, 10.1016/S0140-6736(06)68350-5